Understanding GLP-1 weight loss medications: mechanisms and benefits

Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, which activates both GIP and GLP-1 receptors. Understanding the labeled mechanisms and indications helps set realistic expectations. This article covers what the prescribing information and a major clinical trial say about how these medicines work, their approved uses, and their safety profiles. It does not cover insurance or Medicare coverage, which depends on the current indication, plan, and policy. It is not individualized medical advice; discuss product choice and risks with your clinician.

• Wegovy and Zepbound both reduce calorie intake, likely through effects on appetite; Wegovy acts on GLP-1 receptors, while Zepbound activates both GIP and GLP-1 receptors.
• Benefits are product- and population-specific: in SELECT, semaglutide reduced major adverse cardiovascular events by 20% in adults with cardiovascular disease and overweight or obesity without diabetes, and Zepbound is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity.
• Both medicines carry a boxed warning about thyroid C-cell tumors seen in rodents, and nausea, diarrhea, and constipation are among the most common side effects of each.

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. It acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. Animal studies show that semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.

Semaglutide decreases calorie intake, an effect likely mediated by affecting appetite. It also delays gastric emptying.

Some outcome mechanisms remain uncertain. The label says the exact mechanism for cardiovascular risk reduction has not been established, and the mechanism for MASH is not fully understood. Weight loss and other pathways may contribute, but the label does not support attributing either benefit to one proven pathway.

Wegovy is available in two forms, and both are approved for use with a reduced-calorie diet and increased physical activity. The injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. It also carries an indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Additionally, the injection is approved for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults, under accelerated approval. Wegovy tablets are indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to reduce excess body weight and maintain weight reduction long term in adults with obesity or in adults with overweight and at least one weight-related comorbid condition.

Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It selectively binds to and activates both the GIP and GLP-1 receptors. GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake.

Tirzepatide decreases calorie intake, likely through appetite effects, and delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. This is a product-specific observation from the Zepbound label and does not establish a comparison with semaglutide.

Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. It is also indicated to treat moderate to severe obstructive sleep apnea in adults with obesity.

Product-specific efficacy data come from the labeling and published trials. For semaglutide, the SELECT cardiovascular outcomes trial provides long-term weight and safety data. SELECT included 17,604 adults with preexisting cardiovascular disease and overweight or obesity, without diabetes. Semaglutide showed a 20% reduction in major adverse cardiovascular events. Weight loss continued over 65 weeks and was sustained for up to 4 years. At 208 weeks, semaglutide was associated with a mean reduction in weight of 10.2% and a reduction in waist circumference of 7.7 cm, compared with 1.5% and 1.3 cm for placebo. Clinically meaningful weight loss occurred in both sexes and all races, body sizes, and regions.

Zepbound's weight reduction indication is supported by its own clinical program. Its obstructive sleep apnea indication is based on separate trials in adults with obesity.

Neither label describes a fixed stopping rule for patients who have reached their weight or health goals. In SELECT, weight loss was sustained for up to 4 years with continued treatment. The trial did not test a structured discontinuation phase, so SELECT does not address what happens when the medicine is stopped after long-term use. Obesity is understood as a chronic condition, and treatment decisions about continuing or stopping should be made with a clinician.

The exact mechanism for cardiovascular risk reduction with semaglutide has not been established. For MASH in humans, the precise mechanism of semaglutide is not fully understood and may involve multiple pathways mediated by weight loss and other factors. For tirzepatide, the label states that nonclinical studies suggest GIP may further contribute to regulation of food intake, but this wording is a mechanistic suggestion, not proof that the dual pathway explains all clinical benefits. Head-to-head outcome trials comparing the two products are not covered in the retained evidence.

Eligibility is tied to the labeled indication. Wegovy injection is for adults and pediatric patients aged 12 years and older with obesity, and adults with overweight plus at least one weight-related comorbid condition; the cardiovascular indication adds a requirement for established cardiovascular disease. The MASH indication is for adults with noncirrhotic disease and fibrosis stages F2 to F3. Wegovy tablets share the adult weight and cardiovascular indications. Zepbound is for adults with obesity or overweight with a weight-related condition, and for adults with obesity and moderate to severe obstructive sleep apnea.

Coverage depends on the exact prescribed product, the indication, and the specific plan. Eligibility, contraindications, side effects, route, dosing, and access all matter when choosing a treatment. For current coverage, check the exact prescribed product and indication with the plan rather than relying on general claims.

Both Wegovy and Zepbound labels list common digestive adverse reactions. For Wegovy, the most common adverse reactions (incidence 5% or greater) include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss. For Zepbound, the most common adverse reactions (incidence 5% or greater) are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease.

Wegovy's label carries a boxed warning about thyroid C-cell tumors seen in rodents, and it is unknown whether Wegovy causes these tumors, including medullary thyroid carcinoma, in humans. Zepbound's label carries a boxed warning about thyroid C-cell tumors seen in rats, and it is unknown whether Zepbound causes them in humans. Both products are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Additional warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia (especially with concomitant insulin or insulin secretagogues), acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, serious hypersensitivity reactions including anaphylaxis and angioedema, and diabetic retinopathy complications in patients with type 2 diabetes. Both labels warn about pulmonary aspiration during general anesthesia or deep sedation, and instruct patients to inform healthcare providers of any planned surgeries or procedures. Patients should never share pens.

• Whether your health history matches the labeled indications for Wegovy or Zepbound.
• Your personal or family history of medullary thyroid carcinoma or MEN 2, which would make these medicines contraindicated.
• Any history of pancreatitis, gallbladder disease, or severe stomach problems.
• All other medicines you take, especially insulin, sulfonylureas, or oral medicines with a narrow therapeutic index, because delayed gastric emptying may affect absorption.
• Plans for surgery or procedures requiring anesthesia, and plans for pregnancy or breastfeeding.
• Any symptoms of serious allergic reaction, such as swelling of the face or throat, trouble breathing, or severe rash.
• Severe abdominal pain that will not go away, which requires stopping the medicine and calling a healthcare provider right away.

Wegovy and Zepbound are distinct products with different receptor targets. Wegovy (semaglutide) is a GLP-1 receptor agonist with labeled indications for weight reduction, cardiovascular risk reduction, and MASH with liver fibrosis. Zepbound (tirzepatide) activates both GIP and GLP-1 receptors and is labeled for weight reduction and obstructive sleep apnea in adults with obesity. Both decrease calorie intake through appetite effects and delay gastric emptying, and both carry serious warnings including a boxed warning for thyroid C-cell tumors. Long-term data from SELECT show sustained weight loss with semaglutide over 4 years. What receptor activity means for an individual depends on the whole picture: eligibility, safety, tolerability, access, and a conversation with a clinician.

What is a GLP-1 receptor agonist?

A GLP-1 receptor agonist is a medication that mimics a naturally occurring gut hormone called GLP-1. Semaglutide, for example, decreases calorie intake, likely by affecting appetite, delays stomach emptying, and can lower blood sugar.

Do I have to inject GLP-1 medications, or are there pills?

Both options now exist. Semaglutide (Wegovy) is available as a weekly injection or a daily oral pill. Liraglutide and tirzepatide (Zepbound) are injections. Your clinician can help you weigh the options based on your preferences and health profile.

How much weight can I expect to lose on a GLP-1 medication?

In pivotal trials, STEP-1 reported 14.9% weight loss at 68 weeks with semaglutide 2.4 mg, and SURMOUNT-1 reported 20.9% weight loss at week 72 with tirzepatide 15 mg in people with obesity without diabetes, and results depend on the medication, dose, duration, and individual factors. These are averages, not guarantees. The medicines are approved for use together with a reduced-calorie diet and increased physical activity.

Is tirzepatide (Zepbound) more effective than semaglutide (Wegovy)?

In a head-to-head clinical trial of adults with obesity but without type 2 diabetes, tirzepatide produced an average weight loss of approximately 20.2% of body weight at 72 weeks, compared to approximately 13.7% for semaglutide. The best medication for any individual, however, depends on their full health picture, not efficacy data alone.

What are the most common side effects, and do they go away?

Nausea, vomiting, diarrhea, and constipation are among the most common side effects. With Zepbound, most nausea, vomiting, and diarrhea occurred during dose escalation and decreased over time. The Wegovy label uses gradual dose escalation to reduce gastrointestinal side effects.

Will I regain weight if I stop taking a GLP-1 medication?

Weight regain is common after stopping. In withdrawal studies of semaglutide and tirzepatide, people switched to placebo regained weight, although in one semaglutide extension study participants still had a net loss of 5.6% at week 120, a year after treatment stopped.

Can I take a GLP-1 medication if I do not have diabetes?

Yes. Wegovy and Zepbound are approved for chronic weight management in people who meet the labeled obesity or overweight criteria, regardless of whether they have diabetes.

How long do I have to take these medications?

Extended treatment may be needed to avoid weight regain. The optimal treatment duration is not yet clearly established, and long-term weight-management trials are lacking. This is an ongoing conversation to have with your clinician.

Are GLP-1 medications safe for teenagers?

Wegovy injection is FDA-approved for weight reduction in adolescents 12 and older with obesity. For Wegovy injection, safety and effectiveness for weight reduction have not been established in children under 12, and Wegovy tablets have not been established in pediatric patients, and decisions about use in younger patients should involve a clinician with relevant expertise.

What is the difference between Ozempic and Wegovy if they are both semaglutide?

Both contain the same active ingredient, semaglutide, but they are approved for different indications and come in different doses. Ozempic is approved for type 2 diabetes management. Wegovy is approved for long-term weight reduction in people who meet its obesity or overweight criteria and to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight.

What lifestyle changes should I make while taking a GLP-1 medication?

These medicines are approved for use together with a reduced-calorie diet and increased physical activity. Adequate protein intake and resistance exercise are often recommended to help preserve muscle mass during weight loss. Your care team can help you build a plan that fits your situation.